// App-Quantinova.ai

e21542 : Safety and efficacy of combining pembrolizmumab and dose escalation/fraction de-escalation SRS for melanoma and NSCLC brain metastasis: Preliminary results from arm a of a prospective pilot trial.

Researchers

Presenter

  • Mohammad Khurram Khan

Principal Investigators

  • Tahseen Nasti

  • Lily Masoumy

  • Alice O. Kamphorst

  • Melinda I Yushak

  • Taofeek Kunle Owonikoko

  • Ragini Reiney Kudchadkar

  • Suresh S. Ramalingam

  • David H. Lawson

  • Rafi Ahmed

Medical Centers

  • Emory University, Atlanta, GA

  • Department of Microbiology and Immunology, Emory Vaccine Center, Atlanta, GA

  • Winship Cancer Inst, Atlanta, GA

  • Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA

  • Winship Cancer Institute of Emory University, Atlanta, GA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Peripheral blood mononuclear cell

  • Programmed cell death protein 1

Drug/Treatment

  • Pembrolizumab

Outcome

  • Unknown

Study Design

  • Prospective

  • Dose Escalation

Phase

  • NA

Study Id's

  • NCT02858869

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved